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Prognostic indicators in patients presenting with the nephrotic
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Prognostic indicators in patients presenting with the nephrotic syn-
drome. Clinical data from 246 patients presenting with a nephrotic
syndrome and biopsy-proven glomerular disorder were analyzed, using
statistical survival techniques, to determine which of several variables
(sex, age, plasma creatinine, diastolic blood pressure and 24-hour
urinary protein loss) were associated with subsequent end-stage renal
failure. The best prediction of outcome could be made at one year (N =
121); then plasma creatinine (P < 0.001) and heavy proteinuria (P =
0.049) were the best determinants. For a given plasma creatinine level,
heavy urinary protein was associated with a worse outcome. The
incidence of end-stage renal failure was greatest three to four years
from the date edema first developed. Plasma creatinine and urinary
protein values, collected four-monthly throughout the study period,
were analyzed as time-dependent covariates. A relationship was found
between the prevailing risk of renal failure and earlier heavy proteinuna
(P < 0.001). Spontaneous complete remission of proteinuria was as-
sociated with a highly favorable outcome (P = 0.001) and normal, or
impaired but stable, renal function.
The long-term outcome of patients with histopathologically-
defined glomerular damage needs to be determined to enable an
accurate prognosis to be made and to assess the value of
therapeutic regimens. Usually prognosis has been evaluated for
single histopathological groups; only occasionally have the
groups been compared [1]. Even within such defined groups,
however, the clinical course of individual patients is highly
variable.
We decided to analyze, from our prospective series, a group
of patients from across the histopathological spectrum, but with
a single clinical presentation, that is, a nephrotic syndrome. In
this defined cohort we have sought markers of eventual out-
come.
Life tables and Kaplan-Meier estimates take account of
differing follow-up periods and enable the percentage of survi-
vors in subgroups of patients to be compared [1]. Given a clear
definition of 'onset' and 'end-point', such methods can be used
to study the time interval to, for example, remission of protein-
uria and to any subsequent relapse [2]. The most important
factors in determining a given outcome can be assessed using
multivariate techniques. The Cox 'proportional hazards' regres-
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sion model has been used to discern factors associated with
survival on differing treatments for end-stage renal failure, for
example on hemodialysis [3] or after transplantation [3, 4], and,
more recently, to study factors associated with progression to
renal failure in the natural history of IgA nephropathy [5, 6].
Changes in plasma creatinine were used as end-points for some
analyses in a study of the natural history of a variety of
glomerular pathology [7, 8]. Variables of interest were mea-
sured at a fixed point in time, for example at time of biopsy.
In this report, we explore not only variables at fixed points in
time, but also use time-dependent covariates to analyze data
collected prospectively at sequential follow-up attendances. We
have examined the prognostic value of a selected group of
clinical variables.
This study began prospectively in 1971, when one of us
(NPM), with colleagues at the Manchester Royal Infirmary,
decided to review and to document all such patients and to
follow them on a regular outpatient basis. Patients were seen at
four-monthly intervals, when clinical, biochemical and hema-
tological data were obtained. From 1981, the three present
authors have assembled all the data on computer, and we have
subjected it to statistical analysis. Retrospective data were
available for some patients biopsied between 1960 and 1971;
where appropriate these too were included. All patients had
significant proteinuria (that is, more than 1 g124 hr). We
excluded any patient requiring dialysis within one month of
onset or with diabetic nephropathy. Principal findings on the
444 patients in the study have been reported [91.
In 145 patients the first evidence of disease was asympto-
matic proteinuria detected at a routine medical examination.
These form a highly important subgroup [9] and are the subject
of a separate analysis. We concentrate here on the 246 patients
whose first manifestation of renal disease was the nephrotic
syndrome. Our aim was to examine survival from the date that
edema first appeared until end-stage renal failure (ESRF) su-
pervened, and to determine the prognostic value of certain
clinical and pathological variables.
Methods
Patients
There were 246 patients whose disease first manifested as a
nephrotic syndrome. These occurred between 1948 and 1979,
the majority (94%) after 1961. Actual follow-up ranged from 11
weeks to 33 years, with a median of seven years. The male to
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Table 1. Clinicopathological diagnostic groups
Both
Male Female sexes
Biopsy N % N % N %
Minimal change 24 15% 9 10% 33 13%
No light
microscopic change 12 8% 12 13% 24 10%
Membranous
nephropathy 46 30% 21 23% 67 27%
Mesangial
proliferative with
immunofluorescence:
IgA predominant 1 1 2 1%
1gM predominant 9 41 26% 8 25 28% 17 7%
Other 6 6 12 5%
Not done 25 10 35 14%
Mesangiocapillary 10 6% 11 12% 21 9%
Diffuse
proliferative 5 3% 2 2% 7 3%
Focal segmental
proliferative 4 3% 5 6% 9 4%
Other 14 9% 5 6% 19 8%
Total 156 100% 90 100% 246 100%
female ratio was approximately 2: 1, and the sexes had similar
histopatholoical spectra (Table 1). Mean age at onset was 38
years (SD 19) for men and 36 years (SD 18) for women.
Thirty-one patients had systemic diseases (systemic lupus
erythematosus 15, Henoch Schönlein purpura 3, microscopic
polyarteritis 2 and amyloidosis 11).
Treatment
Diuretics and hypertensive agents were prescribed as clini-
cally indicated. Hypertension was treated immediately it was
confirmed. Thiazides were used as a first line treatment if
diuretics had not been used previously. Antihypertensive
agents (methyldopa and beta-blockers) were used subsequent-
ly.
From 1971, immunosuppressive agents and steroid therapy
were reserved for patients with potentially responsive lesions.
Of 57 patients with 'no significant change' on light microscopy,
33 patients showed a prompt and complete remission of heavy
proteinuria after steroid therapy. This is referred to as minimal
change nephropathy (MCN).
In earlier years, a number of other patients received im-
munosuppressives and/or steroids. Preliminary results do not
suggest the presence of an unsuspected cohort whose disease
remitted on any drug therapy. The only exception may be
membranous nephropathy where, as we have reported [10],
some patients benefitted from 'pulse' steroid therapy.
Variables for analysis
Plasma creatinine (mmol/liter), urinary protein loss (g124 hr),
diastolic blood pressure (mm Hg; obtained at each follow-up
visit), and sex and age at onset were chosen for analysis. The
ratio of the urinary protein to the urinary creatinine output (gig
over the 24 hr period) was calculated to minimize errors caused
by inaccurate collection of urine.
Initially, patients were grouped according to values of these
variables at the onset and at each anniversary (Table 2). Only
Table 2. Groupings for variables showing numbers of patients for
whom data was available
Sex Male 156 (63%)
Female 90 (37%)
Age at onset (years) less than 20 67 (27%)
20 to 34 40 (16%)
35 to 49 61(25%)
50 or more 78 (32%)
At onset At one year
Plasma creatinine mmoliliter
less than 0.12 41(53%) 77 (55%)
0.12 to 0.19 22 (29%) 39 (28%)
0.20 or more 14 (18%) 23 (17%)
Total 77 139
Diastolic blood pressure mm Hg
less than 110 114 (83%) 155 (92%)
110 or more 24 (17%) 13 (8%)
Total 138 168
24-hour urinary protein g
less than 1 0 (0%) 29 (19%)
ito 4.99 19 (21%) 31(21%)
5 to 9.99 26 (29%) 24 (16%)
10 or more 45 (50%) 67 (44%)
Total 90 151
Urinary protein/creatinine ratio gig
less than 4 7 (12%) 42 (34%)
4 to 7.99 23 (40%) 29 (24%)
8 or more 28 (48%) 52 (42%)
Total 58 123
measurements obtained within eight weeks from the relevant
date were used. Our previous work [9] had suggested a 24-hour
urinary protein loss of more than 5 g had significance; in this
analysis we chose cut-off points of 5 and 10 g/24 hr for urinary
protein. Corresponding values for the urinary protein/creatinine
ratios were '4' and '8'. (These were equivalent percentiles for
all available measurements in the study.) A diastolic blood
pressure of 110 mm Hg, uncorrected for age and sex, was
chosen to indicate 'moderate' hypertension; such levels are
associated generally with increased morbidity and mortality,
such as cardiovascular disease. Treatment had often been
initiated at lower levels. 'Mild' hypertension, defined according
to the normotensive limit for the patient's age and sex [11], and
plasma albumin level (g/liter), were also considered in the
multivariate analysis.
Plasma creatinine and albumin were measured using standard
autoanalyzer methods, and urinary protein was measured by a
turbidometric method using salicylsulphonic acid.
Preliminary statistical analysis
Kaplan-Meier survival estimates were calculated for the
whole group, using ESRF, (dialysis, transplantation without
prior dialysis, or death due to renal failure) as the end-point.
Patients who died from other causes were censored. In a
separate analysis we examined deaths, not from renal failure,
but from causes which may have been related to the conse-
quences of prolonged renal disease, such as ischemic heart
disease or cerebro-vascular disease.
For ESRF, survival estimates were calculated for the sub-
groups of patients defined at onset and at one year (Table 2) and
compared by the Mntel-Cox test [12]. Estimates of the 'hazard
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rates' [13] were plotted to ensure that the statistical assump-
tions required for a Cox regression analysis were met.
For patients in whom a complete data set was available, Cox
'proportional hazards' regression analysis [12, 14, 151 was used
to find which of the variables age, sex, plasma creatinine level,
moderate hypertension, and prevailing urinary protein loss,
measured either at onset or at one year, were related indepen-
dently to progression to ESRF. Preliminary analysis established
that urinary protein/creatinine ratio was a more reliable param-
eter than 24-hour urinary protein loss, and that this ratio could
be considered usefully in two subgroups (<4, 4). A reciprocal
transformation for plasma creatinine level gave a more precise
parameter for analysis than the prevailing plasma level. The
year of onset was included to determine whether there was a
trend towards better survival over the study period, since such
a finding would have rendered the data set non-homogeneous.
The statistical significance of each variable in turn was assessed
by deleting the variable and using the likelihood-ratio test.
Once the most important markers of renal outcome were
established, they were compared with the histopathological
diagnosis in the Cox regression analysis by employing a series
of 'dummy' variables for the main biopsy groups.
Statistical analysis using the sequentially collected data
The sequential data collection enabled time trends to be
examined for each individual. With time, the prevailing value
may become a more important indicator of prognosis than the
value at onset or at one year. We therefore considered time-
dependent covariates.
We tested for a significant change in risk of ESRF for those
patients whose proteinuria had remitted spontaneously. Pa-
tients with MCN were excluded. 'Remission' was defined as a
24-hour urinary protein level below 0.3 g, validated by a second
result of less than 0.5 g. Time to first remission was noted, and
a new variable was defined for each patient, giving the value '0'
before remission and '1' after.
We tested then for increase in risk associated with 'heavy' or
'very heavy' proteinuria (equivalent to more than 5 or more
than 10 g/day) at any time. Three 'marker states' were defined
according to the current urinary protein/creatinine ratio (less
than 4; 4 to 7.99; 8 or more) and risks of ESRF were compared
between the states, using the method described by Gail [161.
'Relative risks' were calculated; these were risks associated
with the 'heavy' or 'very heavy' proteinuric states (ratios 4
and 8) compared with the 'best' state (<4).'
In this analysis, we explored whether the risk of reaching
ESRF was better predicted by the marker state 4, 12 or 24
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Fig. 1. Piecewise-constant hazard rate estimates. Numbers of ESRFs
occurring in each 12 month interval divided by the total patient-years at
risk. Symbols are: (—) renal deaths; ( ) other deaths.
months earlier, particularly since, for the patient approaching
ESRF, proteinuria may be reduced because of the fall in GFR.
Finally we incorporated plasma creatinine into the definition
of marker state. Four states were defined, depending on
whether the plasma creatinine level was 0.2 mmol/liter or more
and whether the urinary proteinlcreatinine ratio was above or
below 4 (Table 7).
Results
Preliminary survival analyses
Of 242 patients who had a definable date for onset of edema,
158 (65%) were alive with their own functioning kidneys when
last seen, 44 (18%) progressed to ESRF, and the remainder died
from other causes (ischemic heart disease 8, cerebro-vascular
disease 4, malignancy 5, others 12, and cause unknown 12).
Kaplan-Meier survival estimates for ESRF were 97% at two
years, 85% at five years and 79% at ten years. Plots of the
estimates of the hazard rates suggested a 'peak' risk of ESRF
three to four years from onset (Fig. 1), but no peak was detected
for 'other deaths'.
Comparisons between the subgroups are summarized iii
Table 3. Only two patients progressed to ESRF during the first
year. An elevated plasma creatinine, either at onset or at one
year, and heavy urinary protein loss persisting at one year were
the factors most significantly related to eventual ESRF. A
raised plasma creatinine level, however, did not necessarily
imply that ESRF was inevitable, since we found many patients
in whom levels rose temporarily above 0.2 mmol/liter.
Other factors associated with a worse outcome were male sex
and a diastolic blood pressure of 110 mm Hg or more at onset,
Hypertension
To calculate the 'relative risks', we utilized the marker states for all
patients at the time of each discrete ESRF event. Patients whose
marker states were unknown were temporarily excluded. To estimate
data at dates between follow-up attendances, we used the 'nearest'
result within eight weeks. The 'numbers at risk' at each discrete ES1F
event, the corresponding marker states, and the marker state of the
ESRF patient were determined and this information was substituted
into a log partial likelihood equation [16], which was maximized by
using a library subroutine [18]. The significance of the differences
between states was assessed using the likelihood ratio test. Relative
risks were calculated from resulting estimates of the marker state
coefficients, which we assumed to be constant over time.)
Hypertension was difficult to assess prognostically, since it
was usually treated promptly and rarely persisted. Of the 24
patients who were hypertensive (diastolic pressure 110 mm Hg
or more) at onset, 'control' if defined by two successive levels
below 100 mm Hg, was achieved in all but two patients after a
median of 11 weeks. Levels fell spontaneously for five patients
and, for the remainder, occurred after a median of six weeks
therapy. The cohort with hypertension at one year were previ-
ously untreated; almost all had been normotensive at onset, and
their hypertension was not associated with prognosis.
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Table 3. Comparisons of renal survival in subgroups of patients
Groups
Variable compared Significancea Comments
Sex male vs. female NS (P = 0.053) Worse survival for males
Age years in Table I NS Slight trend towards better survival in
younger patients
Plasma creatinine mmoliliter less than 0.2
vs. 0.2 or more
at onset: P = 0.037
at one year: P < 0.001
Worse survival with increased creatinine
Diastolic blood pressure mm Hg less than 110
vs. 110 or more
at onset: P = 0.037
at one year: NS
Worse survival with increased blood
pressure at onset only
Urinary protein g124 hr less than 5
vs. 5 or more
less than 1
vs. Ito 4.99
5 to 9.99
vs. 10 or more
at onset: NS
at one year: P = 0.005
at one year: NS
at one year: NS
Worse survival with higher levels at one
year only
Urinary protein/creatinine ratio gig less than 4
vs. 4 or more
at onset: NS (P = 0.075)
at one year: P = 0.011
Worse survival with higher levels at on-
set or at one year
a Significance by the Mantel-Cox test. NS, not significant.
Fig. 2. Patients grouped according to their 24-hour urinary protein output (A) and urinary proteinicreatinine ratio (B). Numbers of patients given
in parenthesis. Abbreviations are: M, males; F, females. Symbols are: for A, < I g, 0 1—5 g, P4 5—10 g, U 10 g; for B, El <4 g, PA 4—8 g, U
8+ g.
Two thirds (62%) of patients were hypertensive at some time
in their follow-up, but the levels did not remain high. For
example, they had fallen below 110 (on two successive occa-
sions) within four months in 83% of patients and within eight
months in 91%. Levels fell spontaneously in 46% of patients
and were associated with therapy in the remainder (antihyper-
tensives thiazides 37%, thiazides only 17%). Half of the
patients went on to have further periods of hypertension which
lasted rather longer; levels had fallen in only 70% by four
months, but in 89% by eight months. Spontaneous falls were
less common (28%).
Longitudinal changes
The univariate analyses confirmed the importance of the
variables we had chosen, but there were obvious interrelation-
ships between the variables.
Figures 2A and B show that the percentage of patients with
heavy proteinuria fell with time, and that there was a significant
difference in urinary protein loss between the sexes at onset and
at one year (chi-squared test, P < 0.025 and P < 0.05,
respectively). This may be a reflection of body size, but at one
year, differences between the urinary protein/creatinine ratios
were also significant (P < 0.025). This correction for urinary
creatinine output may adjust for body size, since, unlike urinary
protein output, the ratio did not correlate significantly with
weight and surface area. The fall in urinary protein loss with
time was not attributable exclusively to the death (and so loss
from further analysis) of patients with heavy losses, and a
similar trend was observed within the five-year survivors,
suggesting overall that the underlying lesions in surviving
patients healed gradually.
While overall plasma creatinine levels remained steady (Fig.
3), levels were compared between the sexes after correction for
weight and for surface area. Males had significantly higher
levels at each anniversary from one to five years (Mann-
Whitney U-test, maximum P < 0.05).
The relationship between prevailing heavy urinary protein
loss and plasma creatinine level at onset, one and five years, is
At onset At one year At five years
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Table 5. Cox proportional hazards regression using information at
one year to model renal survival
Coding for the grouped variables
Table 4. Relation
r
ship between prevailing urinary protein/creatinine
atio and plasma creatinine level
Plasma creatinine level at
onset one year five years
Prevailing urinary
protein!
creatinine
ratio
<4 o.lOa 0.09 0.10
0.08—0.24 (6) 0.04—0.34 (41) 0.04—0.69 (48)
>4 0.12 0,12 0.14
0.05—0.53 (47) 0.02—1.13 (80) 0.06—0.97 (18)
NSb P = 0.012 P = 0.007
shown in Table 4. Plasma creatinine levels were significantly
higher for those patients with persisting very heavy proteinuria
(urinary protein/creatinine ratio 4) at one and at five years.
Multivariate analysis of survival-Cox proportional
hazards regression
The data set at onset was incomplete, since this was fre-
quently documented at an outlying hospital. Fifty-two subjects
had adequate data. Of these, the 47 males were analyzed; none
of the five females progressed to ESRF, Only heavy urine
protein loss at Onset (urinary protein/creatinine ratio 4) was
significantly associated with progression to ESRF (P = 0.025).
At one year, 113 patients had complete data sets. Plasma
creatinine level (after transformation) and heavy proteinuria
(ratio 4) were the most significant, independent factors (P <
0.001; P = 0.052 respectively, Table 5A). Sex, age, and
hypertension were not statistically significant. The year of
onset, which ranged from 1961 to 1979 in these patients, did not
influence outcome. This implies prognosis had not changed
over the years of the study.
Sex
Diastolic blood pressure
mm Hg
Urinary protein!creatinine g!g
A. N = 113
Age
Sex
Plasma creatinine
(reciprocal)
Diastolic BP (grouped)
Urinary proteinlcreatinine
ratio (grouped)
Year of onset
B. N 121
Plasma creatinine
(reciprocal)
Urinary protein!creatinine
ratio (grouped)
a Coefficients with associated standard errors (SE) and significance by
the likelihood ratio test. NS = not significant.
Table 6. Kaplan-Meier renal survival estimates for the seven main
histopathological groups
Number At five years At ten years
Minimal change 33 100% 100%
No light microscopic change 23 86% 78%
Membranous nephropathy 65 89% 87%
Mesangial proliferative 65 84% 75%
Mesangiocapillary 21 65% 57%
Diffuse proliferative 7 86% 86%
Focal segmental proliferative 9 88% 88%
An analysis at one year using only plasma creatinine and
heavy proteinuria (121 patients) is shown in Table 5B. Relative
risk of ESRF associated with heavy proteinuria (ratio 4) is exp
(1.3) or 3.5.
In two separate analyses, we included 'mild' hypertension
(defined according to the patients age and sex) and plasma
albumin level at one year. These were not statistically signifi-
cant determinants of outcome.
Biopsy
For the main clinico-pathological subgroups, Kaplan-Meier
estimates at 5 and 10 years are given in Table 6. Only two
groups were significantly different from the others; in MCN no
patient progressed to ESRF; in mesangiocapillary disease
(MCap) prognosis appeared poor. Patients with MCN and
MCap disease differed from the remainder at one year: then the
percentages with urinary protein/creatinine ratio above 4 and
plasma creatinine level above 0.2 mmol/liter were 43% (of 14)
and 7% (of 15) for MCN, 80% (of 10) and 21% (of 14) for MCap
and 66% (of 92) and 19% (of 86) for the remainder. These
findings were not influenced by exclusion of the patients with
underlying systemic diseases.
The numbers of patients in the individual, histopathologically
defined groups were too small for separate multivariate analy-
ses. When biopsy findings were included in the Cox analysis,
Female = 0
<110 = 0
Male =
110 or more
<4 = 0 4ormore =
—0.015 SE 0.014
0.13 SE 0.62
—0.27 SE 0.083
NS
NS
P < 0.001
—0.85 SE 1.0
1.3 SE 0.77
NS
NS (P = 0.052)
—0.007 SE 0.063 NS
—0.27 SE 0.076 P < 0.001
1.3 SE 0.75 P = 0.049Fig. 3. Patients grouped accordihg to their plasma creatinine level.
Numbers of patients given in parenthesis. Abbreviations are: M, males;
F, females. Symbols are: fl <0.12 mmol!liter; 0.12—0.19 mmol!liter;
•  0.2 mmol!liter,
a median, range, (N)
b comparison by two-tailed Mann-Whitney U-test. NS, not signifi-
cant.
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Table 7. Relationship between risk of ESRF and earlier heavy
proteinuria
A. Urinary proteinlcreatinine ratio used to define marker state
Marker state
0 = less than 4
1 = 4 to 7.99
2 = 8 or more
Lag State '1' State '2' P
4 months 2.1 SE 0.62 (8) 3.0 SE 0.57 (20) <0.001
8 months 2.8 SE 0.79 (16) 3.4 SE 0.76 (30) <0.001
1 year 1.2 SE 0.79 (3) 3.0 SE 0.62 (19) <0.001
2 years 1.9 SE 0.72 (6) 2.7 SE 0.66 (15) <0.001
B. Urinary protein/creatinine ratio and plasma creatinine used to define
state
Marker state
0 = Plasma creatinine less than 0.2 mmollliter
urine protein/creatinine ratio less than 4
= Plasma creatinine less than 0.2 mmol/liter
urine protein/creatinine ratio 4 or more
2 = Plasma creatinine 0.2 mmollliter or more
urine protein/creatinine ratio less than 4
3 = Plasma creatinine 0.2 mmol/liter or more
urine protein/creatinine ratio 4 or more
Lag State '1' State '2' State '3' P
1 year 2.8 SE 1.1 (l7) 4.0 SE 1.2 (53) 4.9 SE 1.1 (129) <0.001
a Coefficient for each state, with associated standard error (SE).
Relative risks in parenthesis.
Significance by likelihood ratio test.
the plasma creatinine level and heavy proteinuria together
remained the more significant (P = 0.002 compared with P =
0.070). This indicates that these two clinical variables were
more useful markers of outcome than the histopathological
findings. Further analysis showed that, after allowing for
plasma creatinine and urinary protein loss, histological diagno-
sis was only associated with a worse prognosis (P = 0.038) for
the mesangiocapillary group.
Analyses with time-dependent covariates
A first complete spontaneous remission of proteinuria (to
<0.3 g124 hr) was significantly related to survival (P < 0.001). A
negative coefficient (—2.4 SE 0.74) for remission indicated that
once remission had occurred the risk of ESRF was reduced.
One third of the patients who remitted had a subsequent relapse
(proteinuria >1 g124 hr), but most (93%) of these patients
maintained stable plasma creatinine levels; 75% had levels
within the normal range (<0.12 mmol/liter).
Table 7 documents the second analysis, which tested for
increased risk of ESRF associated with 'heavy' or 'very heavy'
proteinuria 4, 8, 12 or 24 months earlier. Table 7A shows the
three marker states defined according to the urinary protein/cre-
atinine ratio. The baseline for comparison was a ratio less than
'4'. Positive coefficients for the other two states (4 to 7.99 and
8 or more) indicate that these protein losses were associated
with increased risk of ESRF 4, 8, 12 or 24 months later. Relative
risks are shown. Differences between the three states were
statistically highly significant (P < 0.001) for each time lag.
In Table 7B, the prevailing plasma creatinine level also was
taken into account. The baseline for this analysis was a ratio
less than '4' together with a plasma creatinine level less than 0.2
mmollliter. Results for a 12 month lag are shown. A high level
of plasma creatinine (0.2 mmollliter or more) was associated
with an increased risk of ESRF, but heavy urinary protein loss
(ratio '4' or more) was associated with increased risk, whether
or not the plasma creatinine level was high. This analysis was
repeated excluding patients with MCN lesions and patients with
other systemic diseases, and the findings were unchanged.
Discussion
Our findings show that heavy proteinuria (equivalent to
accurately measured urinary protein loss of more than 5 g124 hr)
at one year, together with a raised plasma creatinine, is asso-
ciated with an increased risk of progression to ESRF. The
relationship between increased plasma creatinine and ESRF is
to be expected, since renal failure is determined by the level of
plasma creatinine. We were unable to define a level of plasma
creatinine above which ESRF was inevitable, and therefore
used ESRF as the end point.
In a recent study in Copenhagen [7, 8], time intervals to
defined changes in plasma creatinine state were analyzed, in
addition to progression to ESRF. There are important differ-
ences from our study. First, the authors analyzed all patients
with biopsy-proven glomerulonephritis, irrespective of first
manifestation. Secondly 17 clinical, biochemical and histologi-
cal variables were examined for their prognostic value which
were determined only at the time of biopsy. In this analysis we
have excluded patients with asymptomatic proteinuria. Our
analysis is of patients presenting initially with the nephrotic
syndrome who therefore, by definition, had no previous evi-
dence of renal disease. Other data we have analyzed suggests
that up to one half of patients who appear to present with the
nephrotic syndrome may have had asymptomatic proteinuria
for months or years previously [9].
The greatest risk of ESRF in the patients studied here is at
three to four years after first manifestation. Variables measured
close to onset, or at one year, were considered for prognosis,
since the interval to biopsy was so variable [9]. Although male
patients appear to have a worse outcome, they had higher
plasma creatinine levels and heavier proteinuria at one year,
and when these factors were adjusted (in the multivariate
analysis), male sex was no longer significant. Neither was
hypertension related to outcome but, as we have indicated, this
may be because effective treatment was readily available and
instituted.
Comparisons with other studies are difficult because we have
chosen to look across the histopathological spectrum in a single
center, prospective study. In the recent Copenhagen study, the
authors concluded that histopathology does yield prognostic
information, but only for patients with plasma creatinine level
less than 2 mg/100 ml at biopsy. Other authors have suggested
that some histopathological types can be distinguished fairly
accurately by using clinical and laboratory findings [19]. Our
study differs in approach from that of the Copenhagen workers,
and our experience suggests that clinical variables have more
prognostic value than the broad histopathological diagnosis.
This does not argue against the case for renal biopsy,
however. A biopsy will exclude treatable causes of renal
disease (for example interstitial nephritis), and certain histolog-
ical changes may indicate that a good therapeutic response is
likely, notably with MCN, vasculitic syndromes and possibly
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membranous nephropathy. Furthermore, the development of
sophisticated immunological and biochemical techniques may
eventually broaden our understanding of the pathogenesis and
current activity of the nephropathy.
With regular sequential follow-up, we have been able to
undertake in-depth analyses, to explore the possibility that the
risk of ESRF changes with time, and to examine the relation-
ship between the prevailing measurements and prognosis. Pro-
teinuria, for example, changes with time and may persist, remit
or follow a relapsing and remitting course. We have shown an
association between risk of ESRF and heavy proteinuria and
raised plasma creatinine level up to two years previously. With
the statistical techniques now available, and the disciplined
incorporation of clinical and laboratory measurements, over
extended follow-up, the prognosis of patients will become
defined more accurately.
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